Compugen to Host R&D Day on December 7, 2016 in New York

HOLON,Israel, November 3, 2016 /PRNewswire/ --

November 3, 2016 - Compugen Ltd. (NASDAQ: CGEN) will host an R&D Day in New York City on Wednesday, December 7, 2016, from 9:00 am to 11:00 am ET. A live webcast of the event will be available via the Investors section of Compugen's website at http://www.cgen.com. An audio replay of the meeting will also be available for approximately three months following the meeting on the Company's website.

The R&D Day will focus on the Company's immuno-oncology pipeline, which has been generated through the use of the Company's unique in silico predictive target discovery infrastructure. The event will also feature a presentation by Professor Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center, Johns Hopkins. Prof. Pardoll is the Chairman of Compugen's Scientific Advisory Board and a member of the Board of Directors of Compugen USA Inc., Compugen's wholly-owned US subsidiary.  

Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, stated, "We are very pleased to host an R&D Day focusing on multiple programs in our early-stage immuno-oncology pipeline. We believe that this event, together with new CGEN-15029 program data to be presented next week at the Annual Meeting of the Society for Immunotherapy of Cancer, will demonstrate to our shareholders the substantial medical and commercial potential of our Company's programs."

About Compugen  

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Forward-Looking Statement   

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties, and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: [email protected]
Tel: +972-52-598-9892

SOURCE Compugen Ltd.